SLC5A2 and peripheral arterial disease: Furthermore, in another retrospective cohort study, each of the 11,431 T2DM patients with peripheral artery disease (PAD) taking the SGLT2 inhibitor or DPP-4 inhibitor were analyzed for the risk for ischemic stroke and acute MI after propensity score matching.